SGLT 2 Inhibitors: A New Therapeutic Target And Its Role In Current Clinical Practice

Abstract

Diabetes, one of the major life style diseases, is associated with high morbidity and mortality owing to its microvascular and macrovascular complications. The chance of development of various complications can be effectively prevented by tight glycemic control. We have various groups of drugs like Biguanides, sulfonyl ureas, Glitazones, alpha-glucosidase inhibitors, incretin based therapy, insulin and Insulin analogues in the armamentarium to treat diabetes. But still, the number of patients attaining glycemic targets are relatively low and various adverse effect limit the use of some of these drugs, especially in special groups. Hence there is ongoing research to develop newer and newer drugs which provides sustained blood glucose reduction with minimal adverse effects. SGLT-2 inhibitors are new group of drugs recently approved by FDA to treat Diabetes. In this review we discuss about mechanism of action, various adverse effects and the clinical role of various SGLT-2Inhibitors.